急性早幼粒细胞白血病
三氧化二砷
医学
维甲酸
内科学
随机对照试验
完全缓解
临床试验
胃肠病学
外科
化疗
砷
化学
冶金
材料科学
基因
生物化学
作者
Senlin Luo,Jidong Tian,Xiao Sun,Feifeng Wu,Ying Liu,Wuqing Wan,Zhou She,Chuan Wen
摘要
Objective. To analyze the efficacy, safety, and economy of RIF compared with intravenous arsenic trioxide (ATO) for the induction and consolidation therapy of pediatric APL. Materials and Methods. In this randomized control clinical trial (NCT02200978), children with newly diagnosed APL from June 2013 to December 2017 were randomly divided into RIF and ATO groups. The groups were treated with RIF or ATO in combination with all-trans retinoic acid (ARTA) and conventional chemotherapeutic drugs during induction and consolidation therapy. Results. Ninteen patients were enrolled, including eight in the RIF group and 11 in the ATO group. After induction therapy, the bone marrow morphologic complete remission (CR) rate, the median time to CR, and molecular remission (promyelocytic leukemia protein (PML)/retinoic acid receptor α (RARα) conversion) rates showed no significant differences between patients in the RIF versus ATO groups (100% vs. 100%, p = 1.000 ; 22 vs. 24 days, p = 0.395 ; 28.5% vs. 54.5%, p = 0.367 , resp.). After consolidation therapy, the molecular remission rate was 100% in both groups. At the end of more than two years of follow-up, the disease-free survival (DFS) rate was 100% in both groups. Conclusion. Oral RIF can achieve similar efficacy to intravenous ATO for APL in children with good safety, less toxicity, fewer side effects, and fewer inpatient days. Therefore, oral RIF can be used as an alternative to intravenous ATO for the treatment of APL in children.
科研通智能强力驱动
Strongly Powered by AbleSci AI